235MO Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in younger patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE
作者
S. Loi,Erica Michelle Stringer-Reasor,Jean‐Sébastien Frenel,Mattea Reinisch,Ruth M O’Regan,Michelino De Laurentiis,Y.H. Park,A. O'Dea,Yen‐Shen Lu,V. Gonzalez,Meiqi Gao,Simon H. Waters,Hongzhi Hu,B. Xu